BioSpace News Archive

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced the opening of its new corporate headquarters and laboratory facility located in the heart of South Lake Union – Seattle’s life sciences hub.

Vaxcyte, Inc. today announced that Company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8:40am ET.

Rhythm Pharmaceuticals today announced that Great Britain’s Medicines & Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization to IMCIVREE

Triumvira’s T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, is manufactured using Lonza’s Cocoon ® platform at the C3i Center Inc (C3i) in Montreal

Horizon Therapeutics plc is proud to announce two winning solutions of this year’s Horizon Prize, ThinkGenetic Inc. and Congenica.

Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders announced today that a peer-reviewed paper showed significantly lower seizure risk with NeuroStar® Advanced Therapy for Mental Health than with TMS treatments that claim deeper stimulation with H-Coil technology.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present in a fireside chat format at the Cantor Virtual Global Healthcare Conference on September 28, 2021.

Evaxion Biotech A/S announced today it has promoted its Senior Director, Immuno-Oncology, Birgitte Rønø, Ph.D, to the newly-created position of Chief Scientific Officer, effective immediately.

Neogen Corporation (NASDAQ: NEOG) announced today the results of the first quarter of its 2022 fiscal year, which ended August 31

CuriRx, Inc., a leading contract research (CRO) and product development organization, announced today the launch of their new CuriLytics™ platform with High-Resolution Chemistry Manufacturing and Control (CMC) analytical services.